echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > ESMO Preview Carellizumab plus albumin paclitaxel, positive results of Phase 2 clinical trials are announced

    ESMO Preview Carellizumab plus albumin paclitaxel, positive results of Phase 2 clinical trials are announced

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    The 2022 Annual Meeting of the European Society of Oncology (ESMO) will be held




    Abstract number: 1744P

    :Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study


    Research background


    Several ICIs have become the standard of care for patients with aUC who have progressed (platinum resistance) after platinum chemotherapy, and albumin paclitaxel has also been widely used



    Research design


    The multicenter, one-arm, Phase 2 study included patients who



    Research results


    As of January 2022, a total of 20 eligible patients were included in the



    Conclusions of the study


    Preliminary analysis results show that carellizumab combined with albumin paclitaxel has good antitumor activity and safety


    Reference source:Wang Mumu

    Reviewed: LR

    Executive: Wang Mumu

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.